Liu, Liqin,Lam, Chia-ying Kao,Diedrich, Gundo,Johnson, Leslie S.,Moore, Paul A.,Bonvini, Ezio
申请号：
AU2018224094
公开号：
AU2018224094A1
申请日:
2018.02.22
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen ("TA") (e.g., a "CD137 x TA Binding Molecule"). In one embodiment, such CD137 x TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies. Alternatively, such CD137 x TA Binding molecules will be bispecific trivalent binding molecules. The CD137 x TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions comprising the CD137 x TA Binding Molecules, methods of using the same to treat cancer and other disease and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.
